'Brain Glue' could one day serve as treatment for TBIs

NewsGuard 100/100 Score

Researchers at the University of Georgia's Regenerative Bioscience Center have developed Brain Glue, a substance that could one day serve as a treatment for traumatic brain injuries, or TBIs.

The Brain Glue is a hydrogel matrix with a gelatin-like consistency that acts as a scaffolding for transplanted stem cells, which are capable of repairing damaged tissue. With the unique ability to take the shape of the void left in the brain after a severe trauma, the Brain Glue will enable a more natural healing environment for stem cells to colonize and regenerate.

Lohitash Karumbaiah, assistant professor in UGA's College of Agricultural and Environmental Sciences, led the team that designed and created Brain Glue. The main difference between Brain Glue and other synthetic hydrogels, according to the team, is the variety of possibilities to trap neural stem cells, improve integration and reduce the likelihood of rejection.

"It's very common with these invasive injuries that surgeons will actually remove the part of the dead brain leaving behind a cavity or hole," said Karumbaiah. "The question is, then, can you replace that with something like our Brain Glue, loaded up with compounds native to the brain together with a mix of protective agents that can be incorporated for the best therapeutic outcome.

"The cool thing about this chemistry is that you can take our Brain Glue liquid formulation and then very briefly expose it to long-wave UV light and form a hydrogel in any shape you like," he said.

The new approach is described in the journal ACS Biomaterials Science and Engineering and a recently awarded abstract from the International Brain Injury Association.

For more than two years now, Karumbaiah has been awarded seed-funding for his collaborative TBI work with Maysam Ghovanloo, associate professor of electrical and computer engineering at the Georgia Institute of Technology. The TBI research was initially funded by the Center for Regenerative Engineering & Medicine, known as REM, a collaborative initiative launched in 2011 between the University of Georgia, Emory University and the Georgia Institute of Technology.

The REM collaboration is an extension of Karumbaiah's work to further study neuroplasticity: the brain's ability to self-renew, adapt and compensate for injury and disease. His future studies will focus on how neural networks form and change in response to traumatic insults, and he will investigate the therapeutic use of electrical stimulation to help return loss of function in any given region of the brain.

"Multiple methods are needed in these kinds of studies," said Karumbaiah. "The Brain Glue is where we make the scaffold, and the neuro-network function is really this other arm-;learning how neurons fire and wire together and what this really means in terms of function."

Steven Stice, director of the Regenerative Bioscience Center, is working with Karumbaiah on a licensed technology for commercialization of the new Brain Glue, which was recently named best abstract at a meeting of the International Brain Injury Association.

Karumbaiah's work recently attracted a four-year, $1.5 million research grant from the National Institutes of Health.

"Lohitash sets an example for other junior faculty to emulate," said Stice, GRA Eminent Scholar and D.W. Brooks Professor in CAES. "To be recognized internationally at such an early stage takes great skill and dedication."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unlocking glioblastoma's immune suppression mechanism